SCHEMBL3598928

SCHEMBL3598928

CCOC(=O)C(O)(c1cn(Cc2ccccc2)c2ccc(C(=O)OCc3ccccc3)cc12)C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.48
PTPN1 P18031 1/20 0.44
MAPT P10636 5/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
SERPINE1 P05121 2/20 0.39
KMT2A Q03164 2/20 0.39
CNR2 P34972 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 1/20 0.38
RAD52 P43351 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597849 0.93 F2RL3 (0.46) F2RL3PTPN1MAPTLMNAGAA
SCHEMBL3583780 0.91 F2RL3 (0.47) F2RL3PTPN1MAPTLMNASERPINE1
SCHEMBL3591579 0.85 PTPN1 (0.46) F2RL3PTPN1SERPINE1L3MBTL1
SCHEMBL3592319 0.84 GLA (0.52) F2RL3PTPN1LMNAKMT2ACNR2
SCHEMBL13254021 0.84 PLA2G2A (0.54) PTPN1LMNAKDM4ESERPINE1ALDH1A1
SCHEMBL3598494 0.83 F2RL3 (0.45) F2RL3PTPN1MAPTSERPINE1TP53
SCHEMBL3585213 0.82 PLA2G2A (0.44) F2RL3PTPN1MAPTLMNAKMT2A
SCHEMBL3600955 0.81 PPARG (0.49) PTPN1LMNASERPINE1CNR2L3MBTL1
SCHEMBL3600671 0.80 PTPN1 (0.47) F2RL3PTPN1MAPTLMNASERPINE1
SCHEMBL3600338 0.80 GLA (0.43) F2RL3PTPN1SERPINE1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 F2RL3 555/4885PTPN1 752/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.